Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 7 studies | 22% ± 8% | |
| interneuron | 5 studies | 32% ± 18% | |
| microglial cell | 5 studies | 22% ± 4% | |
| GABAergic neuron | 5 studies | 37% ± 16% | |
| astrocyte | 5 studies | 32% ± 11% | |
| epithelial cell | 4 studies | 27% ± 2% | |
| glutamatergic neuron | 4 studies | 46% ± 13% | |
| oligodendrocyte precursor cell | 4 studies | 25% ± 5% | |
| macrophage | 4 studies | 23% ± 6% | |
| neuron | 4 studies | 32% ± 14% | |
| oligodendrocyte | 4 studies | 26% ± 6% | |
| retinal cone cell | 3 studies | 25% ± 6% | |
| retinal rod cell | 3 studies | 18% ± 4% | |
| type II pneumocyte | 3 studies | 21% ± 4% | |
| transit amplifying cell | 3 studies | 30% ± 15% | |
| adipocyte | 3 studies | 17% ± 1% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 7 studies | 30% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 100% | 975.79 | 180 / 180 | 100% | 26.66 | 430 / 430 |
| esophagus | 100% | 557.79 | 1444 / 1445 | 100% | 15.25 | 183 / 183 |
| intestine | 100% | 638.16 | 966 / 966 | 100% | 23.68 | 526 / 527 |
| stomach | 100% | 616.48 | 359 / 359 | 100% | 21.52 | 285 / 286 |
| prostate | 100% | 743.40 | 245 / 245 | 100% | 26.30 | 500 / 502 |
| breast | 100% | 755.97 | 459 / 459 | 99% | 23.93 | 1112 / 1118 |
| brain | 99% | 528.00 | 2627 / 2642 | 100% | 17.80 | 705 / 705 |
| bladder | 100% | 716.71 | 21 / 21 | 99% | 19.84 | 501 / 504 |
| lung | 99% | 597.22 | 575 / 578 | 100% | 19.23 | 1154 / 1155 |
| thymus | 100% | 802.69 | 653 / 653 | 99% | 20.06 | 600 / 605 |
| skin | 100% | 776.72 | 1808 / 1809 | 99% | 38.32 | 468 / 472 |
| liver | 100% | 784.86 | 226 / 226 | 99% | 15.03 | 401 / 406 |
| uterus | 100% | 858.48 | 170 / 170 | 98% | 16.89 | 451 / 459 |
| pancreas | 100% | 497.24 | 327 / 328 | 98% | 12.38 | 175 / 178 |
| kidney | 100% | 810.89 | 89 / 89 | 98% | 15.11 | 879 / 901 |
| adrenal gland | 100% | 1066.16 | 258 / 258 | 91% | 10.21 | 210 / 230 |
| adipose | 100% | 696.70 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 51.77 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 17.55 | 29 / 29 |
| muscle | 100% | 1105.62 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 603.12 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 11.80 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 6.13 | 1 / 1 |
| blood vessel | 100% | 548.28 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| heart | 95% | 594.23 | 820 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 59% | 458.70 | 544 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006421 | Biological process | asparaginyl-tRNA aminoacylation |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0005759 | Cellular component | mitochondrial matrix |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0003676 | Molecular function | nucleic acid binding |
| GO_0005524 | Molecular function | ATP binding |
| GO_0004816 | Molecular function | asparagine-tRNA ligase activity |
| Gene name | NARS2 |
| Protein name | Asparaginyl-tRNA synthetase 2, mitochondrial Asparaginyl-tRNA synthetase (AsnRS) (NARS2) (EC 6.1.1.22) (Asparagine--tRNA ligase, mitochondrial) asparagine--tRNA ligase (EC 6.1.1.22) |
| Synonyms | |
| Description | FUNCTION: Mitochondrial aminoacyl-tRNA synthetase that catalyzes the specific attachment of the asparagine amino acid (aa) to the homologous transfer RNA (tRNA), further participating in protein synthesis . The reaction occurs in a two steps: asparagine is first activated by ATP to form Asn-AMP and then transferred to the acceptor end of tRNA(Asn) (Probable). . |
| Accessions | ENST00000695346.1 A0A8Q3SHP1 A0A8Q3WKD4 ENST00000695349.1 ENST00000695353.1 A0A8Q3WLT2 ENST00000695343.1 [Q96I59-2] A0A8Q3SHN4 ENST00000529880.1 A0A8Q3SIK4 ENST00000695360.1 A0A8Q3WKD8 A0A8Q3SHN6 ENST00000695344.1 ENST00000695347.1 ENST00000695352.1 ENST00000695357.1 ENST00000695342.1 [Q96I59-2] ENST00000695361.1 ENST00000529771.2 ENST00000695354.1 ENST00000695350.1 ENST00000281038.10 [Q96I59-1] ENST00000695116.1 A0A8Q3WKD2 A0A8Q3WKX6 ENST00000528850.5 [Q96I59-2] E9PRK2 ENST00000695348.1 [Q96I59-2] ENST00000695115.1 [Q96I59-2] A0A8Q3WLI0 ENST00000695366.1 A0A8Q3WKI6 A0A8Q3WKF4 A0A8Q3SHL5 A0A8Q3WKD9 ENST00000695356.1 ENST00000695362.1 A0A8Q3WKE5 A0A8Q3SHT7 ENST00000695355.1 A0A8Q3SHS9 A0A8Q3SHV4 ENST00000695341.1 Q96I59 ENST00000695345.1 ENST00000695351.1 ENST00000695359.1 A0A8Q3SHT5 ENST00000695358.1 H0YE96 A0A8Q3SHU1 |